Assets and Liabilities Held for Sale

3 Months Ended

Jul. 28, 2017

Discontinued Operations and Disposal Groups [Abstract]

In April 2017, the Company entered into a definitive agreement for the sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Minimally Invasive Therapies Group segment. As a result, the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses met the criteria to be classified as held for sale at April 28, 2017 and July 28, 2017, which requires the Company to present the related assets and liabilities as separate line items in the consolidated balance sheets.

The following table presents information related to the assets and liabilities that were classified as held for sale in the consolidated balance sheets:



(in millions)	July 28, 2017		April 28, 2017
Inventories, net	$	369	$	371
Property, plant, and equipment, net	710		689
Goodwill	2,971		2,910
Other intangible assets, net	2,319		2,320
Total assets held for sale	$	6,369	$	6,290

Other accrued expenses	$	59	$	34
Accrued compensation and retirement benefits	12		12
Deferred tax liabilities	880		707
Other liabilities	1		1
Total liabilities held for sale	$	952	$	754

The Company determined that the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses does not meet the criteria to be classified as discontinued operations. The divestiture was completed on July 29, 2017, subsequent to the end of the first quarter of fiscal 2018. See Note 19 to the consolidated financial statements for additional information regarding the completion of the divestiture.

Divestiture-Related Items

Divestiture-related items includes expenses incurred in connection with the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. During the three months ended July 28, 2017, the Company recognized divestiture-related items expense of $47 million, including $22 million of legal and advisory services and $16 million of accelerated stock compensation expense. There were no divestiture-related items expenses for the three months ended July 29, 2016.